The ulcerative colitis (UC) therapy market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz / Xeljanz XR) for moderate to severe disease, together with emerging agents with novel MOAs and a general increase in the use of targeted therapies, will drive market growth. In particular, the availability of non-TNF biologics (e.g., Takeda’s Entyvio, Janssen’s Stelara) and the oral Jak inhibitor Xeljanz / Xeljanz XR will expand physicians’ treatment armamentarium and intensify market competition. Offsetting this growth will be the continued generic erosion of conventional agents and the entry of and increased physician comfort prescribing less-expensive biosimilars, factors that will pose hurdles to the uptake of emerging therapies.

QUESTIONS ANSWERED

  • What are the similarities and differences in the treatment of UC by U.S., European, and Japanese gastroenterologists?
  • How do gastroenterologists perceive biosimilar agents, and what has been/will be their impact on the UC therapy market?
  • What are KOLs’ insights into current treatment options (e.g., Pfizer’s Xeljanz / Xeljanz XR, Janssen’s Stelara)? What factors drive their treatment decisions?
  • What are KOLs’ perceptions of key emerging therapies (e.g., AbbVie’s upadacitinib and risankizumab, Janssen's guselkumab, Bristol Myers Squibb’s ozanimod, Arena’s etrasimod), and where do they see these agents fitting into the treatment algorithm?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Ulcerative Colitis - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • Q3 2020
        • Key Findings
          • Market Outlook
            • Key Findings
              • Market Overview
              • Market Share of Drug Classes for Ulcerative Colitis: 2019
              • Market Share of Drug Classes for Ulcerative Colitis: 2029
              • Patient Share of Ulcerative Colitis Therapies in the Maintenance Setting, by Drug Class: 2019-2029
              • Patient Share of Ulcerative Colitis Therapies in the Acute Setting, by Drug Class: 2019-2029
              • Ulcerative Colitis SWOT Analysis
            • Market Drivers and Constraints
              • What Factors Are Driving the Market for Ulcerative Colitis?
              • What Factors Are Constraining the Market for Ulcerative Colitis?
            • Drug-Class-Specific Trends
              • Total Sales and Patient Share of TNF-Alpha Inhibitors in Ulcerative Colitis: 2019-2029
              • Total Sales and Patient Share of Cell Adhesion Molecule Inhibitors in Ulcerative Colitis: 2019-2029
              • Total Sales and Patient Share of JAK Inhibitors in Ulcerative Colitis: 2019-2029
              • Total Sales and Patient Share of IL Inhibitors in Ulcerative Colitis: 2019-2029
              • Total Sales and Patient Share of S1P-Receptor Modulators in Ulcerative Colitis: 2019-2029
          • Forecast
            • Market Forecast Assumptions
            • Market Forecast Dashboard
          • Etiology and Pathophysiology
            • Key Findings
              • Disease Overview
              • The Four Layers of the Intestinal Wall
              • Anatomical Distribution Patterns of Ulcerative Colitis
              • Typical Symptoms of Acute Ulcerative Colitis Attacks by Disease Severity
            • Etiology
              • The Immune Response
              • Select Gene Targets Associated with Ulcerative Colitis
              • Key Immune and Inflammatory Responses in Ulcerative Colitis
              • The TH2 Response
            • The Inflammatory Cascade
              • Cytokines
              • Lipid Mediators
              • Cell Adhesion Molecules
              • Janus-Activated Kinase
              • Sphingosine-1-Phosphate Receptors
              • Select Inflammatory Mediators
            • Key Pathways and Drug Targets
              • Select Drug Targets and Mechanisms of Action
              • Key Pathways and Select Drug Targets in Ulcerative Colitis
          • Epidemiology
            • Key Findings
              • Epidemiology Populations
                • Disease Definition
                • Methods
                • Sources Used for Diagnosed Prevalent Cases of Ulcerative Colitis
                • Diagnosed Prevalent Cases of Ulcerative Colitis: 2019-2029
                • Drug-Treated Prevalent Cases of Ulcerative Colitis: 2019-2029
            • Current Treatment
              • Key Findings
                • Treatment Goals
                  • Key Endpoints Used in Clinical Trials for Ulcerative Colitis
                • Key Current Therapies
                  • Overview
                  • Mechanism of Action of Key Current Drug Classes Used for Ulcerative Colitis
                  • Current Treatments Used for Ulcerative Colitis
                  • Market Events Impacting the Use of Key Current Therapies for Ulcerative Colitis
                  • Advantages and Disadvantages of Aminosalicylates
                  • Expert Insight: Aminosalicylates
                  • Advantages and Disadvantages of Corticosteroids
                  • Expert Insight: Corticosteroids
                  • Advantages and Disadvantages of Immunosuppressants
                  • Expert Insight: Immunosuppressants
                  • Advantages and Disadvantages of Infliximab
                  • Advantages and Disadvantages of Adalimumab
                  • Advantages and Disadvantages of Simponi
                  • Expert Insight: TNF-Alpha Inhibitors
                  • Advantages and Disadvantages of Entyvio
                  • Expert Insight: Entyvio
                  • Ongoing Clinical Development
                  • Key Ongoing Clinical Trials of Entyvio in the Treatment of Ulcerative Colitis
                  • Advantages and Disadvantages of Xeljanz / Xeljanz XR
                  • Expert Insight: Xeljanz / Xeljanz XR
                  • Ongoing Clinical Development
                  • Key Ongoing Clinical Trials of Xeljanz / Xeljanz XR in the Treatment of Ulcerative Colitis
                  • Advantages and Disadvantages of Stelara
                  • Ongoing Clinical Development of Stelara
                  • Key Ongoing Clinical Trials of Stelara in the Treatment of Ulcerative Colitis
                • Medical Practice
                  • Overview
                  • Country-Specific Ulcerative Colitis Treatment Guidelines
                  • Factors Influencing Drug Selection in Ulcerative Colitis
                  • Treatment Decision Tree for Ulcerative Colitis: United States
                  • Treatment Decision Tree for Ulcerative Colitis: Europe
                  • Treatment Decision Tree for Ulcerative Colitis: Japan
              • Unmet Need Overview
                • Current and Future Attainment of Unmet Needs in Ulcerative Colitis
                • Top Unmet Needs in Ulcerative Colitis: Current Attainment and Future Attainment
                • Expert Insight: Unmet Need in Ulcerative Colitis
              • Emerging Therapies
                • Key Findings
                  • Pipeline Trends in Ulcerative Colitis
                • Key Emerging Therapies
                  • Key Therapies in Development for Ulcerative Colitis
                  • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Ulcerative Colitis
                • Early-Phase Pipeline Analysis
                  • Select Compounds in Phase II Development for Ulcerative Colitis
                • Key Discontinuations and Failures in Ulcerative Colitis
                • Access and Reimbursement Overview
                  • Region-Specific Reimbursement Practices
                  • Appendix
                    • Key Abbreviations Related to Ulcerative Colitis
                    • Brands, Marketers, and Generic Availability of Current Therapies Used for Ulcerative Colitis, by Market
                    • Ulcerative Colitis Bibliography

                Author(s): Ritesh Gupta, Ph.D.; Abey John, M.P.H.

                Ritesh Gupta, Ph.D., is a manager in the Immune and Inflammatory Disorders team at Clarivate. He has years of experience in competitive intelligence, scientific analysis, and market opportunity assessment and has worked in various therapeutic areas to provide strategic recommendations to pharmaceutical companies. He holds a Ph.D. in cell biology from the Max Delbrück Center for Molecular Medicine in Berlin.

                Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.

                 


                Related Reports

                Ulcerative Colitis | Disease Landscape and Forecast | G7 | 2020

                The ulcerative colitis (UC) therapy market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz / Xeljanz XR) for moderate to severe di...

                View Details

                Ulcerative Colitis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) Dashboard

                Ulcerative colitis (UC) is a chronic inte...

                View Details

                Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Adult | US | 2020

                Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum, characterized by diarrhea, abdominal pain, rectal bleeding, fever, and weight loss. The prima...

                View Details

                Ulcerative Colitis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) 2020

                Ulcerative colitis (UC) is a chronic inte...

                View Details